trending Market Intelligence /marketintelligence/en/news-insights/trending/q9PzGEUX3vj6jXW6X08yjg2 content esgSubNav
In This List

Repros Therapeutics likely to get negative EU opinion on hypogonadism drug

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Repros Therapeutics likely to get negative EU opinion on hypogonadism drug

Repros Therapeutics Inc. said its marketing application for enclomiphene in secondary hypogonadism is likely to receive a negative opinion in January 2018 from a European Medicines Agency committee.

The company received feedback regarding the forthcoming option, which will be issued by the Committee for Medicinal Products for Human Use, following an oral explanation.

The application was submitted by Renable Pharma Ltd., the company's U.K. unit.

Hypogonadism is a form of testosterone deficiency in adult males.

Allergan plc is in the process of acquiring Repros Therapeutics.